Summary of the Conference Call for 康龙化成 (Kanglong Chemical) Company Overview - 康龙化成 is a leading player in the pharmaceutical and biotechnology services industry, focusing on laboratory services, small molecule CDMO (Contract Development and Manufacturing Organization), and clinical services. Key Financial Highlights - In 2025, the company achieved revenue of 140.95 billion CNY, a year-on-year increase of 14.8% [3] - Adjusted net profit was 18.16 billion CNY, up 13% year-on-year, while net profit attributable to shareholders decreased by 7.2% due to significant investment gains in 2024 [3] - Revenue from the top 20 global pharmaceutical companies grew by 29.4%, accounting for 20% of total revenue [3] - New orders increased by over 14% year-on-year, with more than 950 new clients contributing approximately 4% to revenue [3] Business Segment Performance Laboratory Services - Revenue reached 81.59 billion CNY, a 15.8% increase year-on-year, with a gross margin of 44.7% [5] - The segment participated in 887 global new drug discovery projects, showing an increase from 2024 [5] - The growth was driven by the integration of AI and automation technologies, enhancing research efficiency [5] Small Molecule CDMO - Revenue was 34.83 billion CNY, up 16.5% year-on-year, with a gross margin of 33.8% [6] - The segment saw significant order growth, particularly in the second half of the year, with Q4 revenue reaching 11.9 billion CNY [6] - The number of late-stage projects increased significantly, with 47 Phase III projects and 34 commercial projects [7] Clinical CRO Services - The clinical business saw a slight increase in new orders, with overseas business achieving double-digit growth, accounting for over 35% of total revenue [14] - Domestic CRO and SMO services showed modest growth, with signs of price recovery in the market [14] Strategic Developments - The company made significant strides in commercialization, with API production facilities in Ningbo and Shaoxing passing FDA inspections, leading to the approval of its first commercial API for the U.S. market [3][12] - A major commercial agreement was signed with a multinational corporation for the production of oral small molecule GLP-1 formulations [3] - The ADC (Antibody-Drug Conjugate) production facility has been launched, and a new large-scale peptide API solid-phase synthesis facility is expected to be completed by 2026 [6][11] Market Outlook - For 2026, the company projects revenue growth of 12% to 18%, with a strong order pipeline and expected acceleration in CDMO revenue growth [8][15] - The company anticipates that the CDMO segment will continue to outpace overall company growth, with further improvements in revenue share and profitability [8][10] - The company is well-positioned to leverage its integrated service platform and technological advancements to attract more clients and enhance service delivery [15] Risks and Challenges - Potential impacts from currency fluctuations, particularly the appreciation of the RMB against the USD, are acknowledged, but the company expects revenue growth to offset these effects [8][15] - The clinical business may still be influenced by low-priced orders signed in previous years, affecting revenue in 2026 [14] Conclusion - 康龙化成 demonstrated robust growth in 2025, with strong performances across its core business segments. The company is optimistic about its future prospects, driven by a solid order backlog and strategic partnerships, despite facing some external economic challenges [16][17]

Group 1: Market Demand and Growth - The biotech client segment is experiencing a mild recovery, driven by capital market improvements, technological breakthroughs, and ongoing clinical applications [2] - The Chinese market has seen a year-on-year growth of 21%, significantly faster than the first half of the year, attributed to increased project delivery pace [3] - The overall market demand outlook remains optimistic, with significant contributions from late-stage clinical projects [2] Group 2: Financial Performance and Cost Management - The company has achieved a strong recovery in overall profitability this year, with effective high-value commercialization projects and cost reduction measures [2] - Expenses have decreased by 13% year-on-year in the first three quarters, with further cost reduction potential anticipated [3] - The gross profit margin is expected to continue improving if market demand remains stable and production capacity utilization increases [2] Group 3: Capacity and Production - The main production capacity for small molecule APIs is distributed across several locations, with ongoing improvements in utilization rates in Chongqing and Jiangxi [4] - There are structural differences in capacity utilization, with some facilities operating at saturation while others require optimization [4] - The company is focusing on enhancing existing capacity utilization rather than expanding new capacity [4] Group 4: Strategic Focus and Future Outlook - The company aims to identify key market opportunities amid changing customer demand and supply chain strategies [3] - The cardiovascular, renal, and metabolic (CVRM) sectors are highlighted as areas with significant potential for small molecule demand [3] - Continuous organizational and process reforms are being implemented to enhance operational efficiency and competitiveness [4] Group 5: Talent and Recruitment - The overall employee count has seen a stable increase, with some structural adjustments to meet company needs [4] - The talent supply environment is characterized by a need for suitable candidates that align with the company's requirements [4]

Core Insights - The report from Xinda Securities highlights that Jiuzhou Pharmaceutical's CDMO business is experiencing high growth, with new molecular business layouts expected to create additional growth points [1] Group 1: CDMO Business Growth - As of H1 2025, the company has undertaken a total of 1,214 projects in innovative drug raw material CDMO, including 1,086 projects in clinical phases I and II, which is an increase of 60 projects compared to the end of 2024 [1] - The number of clinical phase III projects stands at 90, reflecting an increase of 6 projects from the end of 2024, while commercial projects have reached 38, with an increase of 3 projects [1] - The projects cover various therapeutic areas such as anti-tumor, anti-heart failure, anti-viral, central nervous system, and cardiovascular treatments, indicating a growing number of late-stage and commercial projects that are likely to drive sustained performance growth for the company [1] Group 2: New Molecular Business Development - The company has established a comprehensive technical platform for new molecular businesses, including peptides, conjugates, and small nucleic acid drugs [1] - In H1 2025, the new molecular business has attracted over 20 new clients, with a rapid increase in overseas orders, having completed the delivery of more than ten projects [1] Group 3: Market Potential - According to Frost & Sullivan, the global ADC and broader conjugate drug CRDMO market was valued at $1.5 billion in 2022, with expectations to grow to $11 billion by 2030, representing a compound annual growth rate (CAGR) of 28.4% from 2022 to 2030 [1]

Investment Rating - The investment rating for the company is not explicitly stated in the provided documents, but the overall sentiment appears positive based on the growth metrics and strategic initiatives discussed. Core Insights - The company has demonstrated stable operational trends with high growth in its CDMO (Contract Development and Manufacturing Organization) business, achieving a revenue of 22.91 billion yuan in H1 2025, a year-on-year increase of 16.27% [2] - The new molecular business layout is expected to create new growth points, with significant investments in peptide, conjugate, and small nucleic acid drug platforms [4][5] Summary by Sections Financial Performance - In H1 2025, the company reported total revenue of 28.71 billion yuan, a 3.86% increase year-on-year, and a net profit attributable to shareholders of 5.26 billion yuan, reflecting a 10.70% growth [1] - The operating cash flow net amount reached 8.45 billion yuan, marking a substantial increase of 164.50% [1] CDMO Business - The CDMO segment continues to thrive, with a revenue of 22.91 billion yuan in H1 2025, maintaining a gross margin of 41.02% [2] - The project pipeline has expanded significantly, with 1,214 projects under contract, including 1,086 in clinical phases I and II, and 90 in phase III [2] API Business - The API (Active Pharmaceutical Ingredient) business saw a decline in revenue to 5.23 billion yuan, down 28.48% year-on-year, attributed to reduced demand for respiratory disease-related products [3] New Molecular Business - The company is actively expanding its new molecular business, having onboarded over 20 new clients in H1 2025, with a notable increase in overseas orders [4] - The global market for TEDIS (including peptides and oligonucleotides) CRDMO is projected to grow from 5.5 billion USD in 2023 to 37.3 billion USD by 2032, with a CAGR of 23.8% [5] Financial Projections - Revenue projections for 2025-2027 are 55.09 billion yuan, 61.77 billion yuan, and 68.42 billion yuan respectively, with net profits expected to be 9.28 billion yuan, 10.66 billion yuan, and 12.07 billion yuan [7]

Group 1: Impact of External Factors - The geopolitical factors, such as the Biosecurity Act, influence clients' strategies, leading them to seek multiple suppliers to manage supply chain risks [1] - Current tariff policies have limited impact on the company, as less than 5% of its revenue comes from direct exports to the U.S., and products fall within the tariff exemption range [2] Group 2: Financial Performance - The company's overall gross margin fluctuates mainly due to domestic market conditions and losses in new business, while overseas market and core business margins remain stable [3] - In Q1 2025, the new molecular business generated approximately CNY 14.19 million in revenue, reflecting a year-on-year growth of about 353% [7] Group 3: Production Capacity and Orders - The company has expanded its production and R&D capabilities through acquisitions and the establishment of new centers, including factories in Hubei and Shanghai [4] - The order conversion cycle typically ranges from 6 to 18 months, with some orders taking 2 to 3 years to convert into revenue [6] Group 4: Future Investments - The capital expenditure for 2025 will focus on overseas expansion, new molecular technology development, and upgrading existing small molecule production capacity [8]